Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Zongertinib (BI 1810631) 是一种不可逆的 HER2 TKI,可抑制 EGFR 信号传导并改善临床前模型和 HER2 驱动癌症患者的治疗反应
期刊:Cancer Discovery
影响因子:29.7
doi:10.1158/2159-8290.CD-24-0306
Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, Yukina Shirai, Masachika Ikegami, Sylvia Tilandyová, Dirk Scharn, Mark A Pearson, Johannes Popow, Anna C Obenauf, Noboru Yamam